World Health Organization and Global Partners Mobilize 70,000 Emergency Vaccine Doses to Contain Accelerating Health Crisis in DR Congo

GENEVA / KINSHASA — In an urgent international mobilization to halt an accelerating public health emergency, the World Health Organization (WHO) and the International Coordinating Group (ICG) on Vaccine Provision have approved the immediate deployment of 70,000 doses of the Ervebo vaccine to the Democratic Republic of the Congo (DRC). The vital intervention aims to establish an immediate protective shield around high-risk medical personnel while launching an unprecedented real-world clinical evaluation against an evolving viral epidemic. The current epidemiological surge across several central and eastern provinces has placed immense strain on local healthcare systems, with recorded cases surpassing 5,000 and documented fatalities climbing past 2,400 since early May. Compounding the complexity of the response is the specific viral etiology driving the surge: the Bundibugyo strain. While the Ervebo vaccine was originally formulated and clinically licensed to target the Zaire ebolavirus strain, global health regulators are deploying the formulation under structured compassionate-use and observational trial frameworks to evaluate its cross-reactive protective efficacy. The strategic release of the 70,000 doses from the international emergency reserve is partitioned into two critical operational avenues. The majority allocation, comprising 50,000 doses, is being funneled directly to frontline clinical personnel, emergency triage nurses, laboratory diagnostic technicians, and…